{"id":{"repo_id":"mit","oai_identifier":"oai:dspace.mit.edu:1721.1/162746"},"canonical_url":"https://search.dev.ndltd.org/etd/mit/oai:dspace.mit.edu:1721.1/162746","repository":{"repo_id":"mit","name":"MIT","base_url":"https://dspace.mit.edu/oai/request"},"display":{"title":"Association of GLP-1 Receptor Agonist Use with Kidney and Cardiovascular Outcomes in Stable Kidney Transplant Recipients","abstract":"Recent surges in the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown promise in reducing cardiovascular events and improving kidney function in patients with type 2 diabetes. Due to these hopeful improvements, kidney transplant recipients (KTRs) have started using GLP-1RA. However, their effects in KTRs remain largely unstudied in clinical studies. This thesis uses a large-scale Electronic Health Record (EHR) database to perform a retrospective cohort analysis to study the association between GLP-1RA use and kidney and cardiovascular outcomes amongst stable KTRs. Primary outcomes include all-cause mortality, major adverse kidney events (MAKE), and major adverse cardiac events (MACE). Among stable KTRs, GLP-1RA users show reduced risk for all-cause mortality (adjusted hazard ratio [aHR]: 0.45; 95% confidence interval [CI]: 0.32-0.62) and MAKE (aHR: 0.69; 95% CI: 0.58-0.81), but no significant difference for MACE (aHR: 0.84; 95% CI: 0.67-1.05). In addition, users show increased risk for irritable bowel syndrome (IBS) (aHR: 2.11; 95% CI: 1.07-4.15) and urinary tract infection (UTI) (aHR: 1.53; 95% CI: 1.27-1.85). These results indicate the potential of GLP-1RA to reduce mortality and adverse kidney outcomes and increase IBS and UTI in KTRs.","abstract_html":"Recent surges in the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown promise in reducing cardiovascular events and improving kidney function in patients with type 2 diabetes. Due to these hopeful improvements, kidney transplant recipients (KTRs) have started using GLP-1RA. However, their effects in KTRs remain largely unstudied in clinical studies. This thesis uses a large-scale Electronic Health Record (EHR) database to perform a retrospective cohort analysis to study the association between GLP-1RA use and kidney and cardiovascular outcomes amongst stable KTRs. Primary outcomes include all-cause mortality, major adverse kidney events (MAKE), and major adverse cardiac events (MACE). Among stable KTRs, GLP-1RA users show reduced risk for all-cause mortality (adjusted hazard ratio [aHR]: 0.45; 95% confidence interval [CI]: 0.32-0.62) and MAKE (aHR: 0.69; 95% CI: 0.58-0.81), but no significant difference for MACE (aHR: 0.84; 95% CI: 0.67-1.05). In addition, users show increased risk for irritable bowel syndrome (IBS) (aHR: 2.11; 95% CI: 1.07-4.15) and urinary tract infection (UTI) (aHR: 1.53; 95% CI: 1.27-1.85). These results indicate the potential of GLP-1RA to reduce mortality and adverse kidney outcomes and increase IBS and UTI in KTRs.","abstract_has_math":false,"creators":["Jung, Emma Yejoo"],"institution":"Massachusetts Institute of Technology","degree_name":"Master","degree_level":null,"degree_discipline":null,"degree_department":"Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science","school":null,"contributors":[],"advisors":["Rinard, Martin"],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025-05","date_published":"2025-05","updated_at":"2026-07-22T22:21:22Z","subjects":[],"languages":[],"rights":["In Copyright - Educational Use Permitted","Copyright retained by author(s)"],"rights_urls":["https://rightsstatements.org/page/InC-EDU/1.0/"],"identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/1721.1/162746","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Rinard, Martin"]},{"key":"dc:contributor.department","label":"Department","values":["Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science"]},{"key":"dc:creator","label":"Author","values":["Jung, Emma Yejoo"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2025-09-18T14:30:19Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2025-09-18T14:30:19Z"]},{"key":"dc:date.issued","label":"Date","values":["2025-05"]},{"key":"dc:publisher","label":"Institution","values":["Massachusetts Institute of Technology"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master","Master of Engineering in Electrical Engineering and Computer Science"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:rights","label":"Dc Rights","values":["In Copyright - Educational Use Permitted","Copyright retained by author(s)"]},{"key":"dc:rights.uri","label":"Rights URI","values":["https://rightsstatements.org/page/InC-EDU/1.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/1721.1/162746"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Recent surges in the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown promise in reducing cardiovascular events and improving kidney function in patients with type 2 diabetes. Due to these hopeful improvements, kidney transplant recipients (KTRs) have started using GLP-1RA. However, their effects in KTRs remain largely unstudied in clinical studies. This thesis uses a large-scale Electronic Health Record (EHR) database to perform a retrospective cohort analysis to study the association between GLP-1RA use and kidney and cardiovascular outcomes amongst stable KTRs. Primary outcomes include all-cause mortality, major adverse kidney events (MAKE), and major adverse cardiac events (MACE). Among stable KTRs, GLP-1RA users show reduced risk for all-cause mortality (adjusted hazard ratio [aHR]: 0.45; 95% confidence interval [CI]: 0.32-0.62) and MAKE (aHR: 0.69; 95% CI: 0.58-0.81), but no significant difference for MACE (aHR: 0.84; 95% CI: 0.67-1.05). In addition, users show increased risk for irritable bowel syndrome (IBS) (aHR: 2.11; 95% CI: 1.07-4.15) and urinary tract infection (UTI) (aHR: 1.53; 95% CI: 1.27-1.85). These results indicate the potential of GLP-1RA to reduce mortality and adverse kidney outcomes and increase IBS and UTI in KTRs."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["M.Eng."]},{"key":"dc:title","label":"Title","values":["Association of GLP-1 Receptor Agonist Use with Kidney and Cardiovascular Outcomes in Stable Kidney Transplant Recipients"]}]}],"canonical_facts":{"dc:contributor.advisor":["Rinard, Martin"],"dc:contributor.department":["Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science"],"dc:creator":["Jung, Emma Yejoo"],"dc:date.accessioned":["2025-09-18T14:30:19Z"],"dc:date.available":["2025-09-18T14:30:19Z"],"dc:date.issued":["2025-05"],"dc:description.abstract":["Recent surges in the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown promise in reducing cardiovascular events and improving kidney function in patients with type 2 diabetes. Due to these hopeful improvements, kidney transplant recipients (KTRs) have started using GLP-1RA. However, their effects in KTRs remain largely unstudied in clinical studies. This thesis uses a large-scale Electronic Health Record (EHR) database to perform a retrospective cohort analysis to study the association between GLP-1RA use and kidney and cardiovascular outcomes amongst stable KTRs. Primary outcomes include all-cause mortality, major adverse kidney events (MAKE), and major adverse cardiac events (MACE). Among stable KTRs, GLP-1RA users show reduced risk for all-cause mortality (adjusted hazard ratio [aHR]: 0.45; 95% confidence interval [CI]: 0.32-0.62) and MAKE (aHR: 0.69; 95% CI: 0.58-0.81), but no significant difference for MACE (aHR: 0.84; 95% CI: 0.67-1.05). In addition, users show increased risk for irritable bowel syndrome (IBS) (aHR: 2.11; 95% CI: 1.07-4.15) and urinary tract infection (UTI) (aHR: 1.53; 95% CI: 1.27-1.85). These results indicate the potential of GLP-1RA to reduce mortality and adverse kidney outcomes and increase IBS and UTI in KTRs."],"dc:description.degree":["M.Eng."],"dc:identifier.uri":["https://hdl.handle.net/1721.1/162746"],"dc:publisher":["Massachusetts Institute of Technology"],"dc:rights":["In Copyright - Educational Use Permitted","Copyright retained by author(s)"],"dc:rights.uri":["https://rightsstatements.org/page/InC-EDU/1.0/"],"dc:title":["Association of GLP-1 Receptor Agonist Use with Kidney and Cardiovascular Outcomes in Stable Kidney Transplant Recipients"],"dc:type":["Thesis"],"thesis:degree_name":["Master","Master of Engineering in Electrical Engineering and Computer Science"]},"updated_at":"2026-07-22T22:21:22Z"}